← Back to headlines
Xeris Biopharma Reports Q4 Top-Line Beat and 2026 Revenue Guidance
Xeris Biopharma saw its stock rise following a strong Q4 top-line performance and positive revenue guidance for 2026.
2 Mar, 17:08 — 2 Mar, 17:08
ℹOnly 1 source covers this story
